Erica Andrews

FDG-PET/CT is gaining attention for its role in staging and restaging breast cancer. A trial from the Technical University of Munich, presented Sunday at the 2008 Society of Nuclear Medicine meeting in New Orleans, found that PET/CT detected local or distant recurrence in 67% of breast cancer patients and changed the management plan in 33% of the cases.